Skip to Content
MilliporeSigma
All Photos(1)

Documents

S-024

Supelco

HU-210 solution

100 μg/mL in methanol, (Spice Cannabinoid), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H38O3
CAS Number:
Molecular Weight:
386.57
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule E (Switzerland)

concentration

100 μg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology
forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CCCCCCC(C)(C)c1cc(O)c2[C@@H]3CC(CO)=CC[C@H]3C(C)(C)Oc2c1

InChI

1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m1/s1

InChI key

SSQJFGMEZBFMNV-WOJBJXKFSA-N

General description

HU-210 is a synthetic cannabinoid found in the herbal mixture “Spice.” Illicit use of this Spice cannabinoid includes smoking the herbal product to obtain a psychoactive effect. Structurally similar to (-)-Δ8-THC and 11-Hydroxy-Δ9-THC, HU-210 is considerably more potent than natural THC from cannabis and has an extended duration of action.
In July, 2009, the US Drug Enforcement Agency (DEA) placed HU-210 on its Drugs and Chemicals of Concern list. Since HU-210′s placement on this list, DEA has reported seizures of Spice herbal mixtures in Ohio and Florida. HU-210 is currently listed as a Schedule I controlled substance. In recognition of this regulatory challenge, Cerilliant supplies its certified HU-210 reference standard in a convenient, quantitative, DEA-exempt solution.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

wgk_germany

WGK 1

flash_point_f

closed cup

flash_point_c

closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

CP-55940 >98% (HPLC), powder

Sigma-Aldrich

C1112

CP-55940

JWH-015 ≥98% (HPLC), powder

Sigma-Aldrich

J4252

JWH-015

AM251 >98% (HPLC), solid

Sigma-Aldrich

A6226

AM251

Supelco

Supelco

S-065

AB-FUBINACA solution

(±)-Δ9-THC solution 100 μg/mL in heptane, ampule of 1 mL, Cerilliant®

Supelco

T-047

(±)-Δ9-THC solution

Cannabidiol solution 1.0 mg/mL in methanol, analytical standard, for drug analysis

Supelco

C6395

Cannabidiol solution

S E M Lewis et al.
International journal of andrology, 35(5), 731-740 (2012-03-23)
Recent societal acceptance of cannabinoids as recreational and therapeutic drugs has posed a potential hazard to male reproductive health. Mammals have a highly sophisticated endogenous cannabinoid (ECS) system that regulates male (and female) reproduction and exo-cannabinoids may influence it adversely.
C L Limebeer et al.
British journal of pharmacology, 167(5), 1126-1136 (2012-06-08)
Conditioned gaping reactions reflect nausea-induced behaviour in rats. Cannabinoid 1 receptor (CB(1) ) agonists interfere with the establishment of nausea-induced conditioned gaping; however, it is not known if their effects are mediated by an action at peripheral or central CB(1)
Bob Roozenbeek et al.
Critical care medicine, 40(5), 1609-1617 (2012-04-19)
The International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury prognostic models predict outcome after traumatic brain injury but have not been compared in large datasets. The objective of this is study is
Rizi Ai et al.
Journal of molecular graphics & modelling, 38, 155-164 (2012-10-20)
Cannabinoid (CB1) receptor is a therapeutic drug target, and its structure and conformational changes after ligand binding are of great interest. To study the protein conformations in ligand bound state and assist in drug discovery, CB1 receptor homology models are
Vu H Nguyen et al.
Pharmacology, 89(1-2), 64-73 (2012-02-04)
Functional linkages between the cannabinoid CB(1) and the dopaminergic systems have been reported although the observations and the mechanisms hypothesizing their interactions at the G protein-coupled receptor (GPCR) functionality level are conflicting. Administration of a potent cannabinoid agonist, HU210, at

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service